Analgesic efficacy of non-invasive neuromodulation techniques in chronic cancer pain: a systematic review

被引:0
作者
Grenouillet, Solene [1 ]
Balayssac, David [2 ]
Moisset, Xavier [2 ]
Peyron, Roland [1 ]
Fauchon, Camille [2 ]
机构
[1] Jean Monnet Univ, CHU Hop Nord, Inserm,CNRS, NEUROPAIN Team,CRNL, St Etienne, France
[2] Univ Clermont Auvergne, NEURO DOL, Inserm, CHU Clermont Ferrand, Clermont Ferrand, France
关键词
Non-invasive brain stimulation; Cancer-related pain; Neuropathic pain; Non-pharmacological treatments; Systematic review; TRANSCRANIAL MAGNETIC STIMULATION; INDUCED PERIPHERAL NEUROPATHY; MOTOR CORTEX; PREVALENCE; NEUROSTIMULATION; GUIDELINES; MANAGEMENT; THERAPY;
D O I
10.1007/s00520-025-09378-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Chronic pain remains one of the most frequent and disabling symptoms of cancer, arising from tumors and/or treatments, and is poorly controlled in 40% of patients. Non-invasive brain stimulation (NIBS) is now widely recommended in drug-refractory neuropathic pain, but its effectiveness in chronic cancer-related pain remains unknown. A few observational studies and randomized controlled trials (RCTs) have assessed the effectiveness of NIBS on pain in this population. Methods A systematic review of neuromodulation studies on patients with chronic cancer-related pain involving transcranial direct currents stimulation (tDCS) or repetitive transcranial magnetic stimulation (rTMS) was conducted to estimate the analgesic efficacy, safety and feasibility in clinical routine. Results Eleven publications (N = 298 patients) were included and analyzed. For tDCS, three RCT had a moderate effect size of 0.7 [0.6; 0.9] on a rating scale (0-10), and two case reports showed a significant decrease of pain intensity on average by -4.25 +/- 0.36 points. The rTMS provided similar pain relief, with two RCTs showing a large effect size of 0.9 [0.7; 1.1], two observational study studies reporting a significant pooled effect on pain intensity (-0.9 [-1.6; -0.1] and -2.3 [-3.3; -1.3]), and two case reports where pain was reduced on average by -4.75 +/- 0.36 points. None of these studies reported serious adverse events, and discontinuations of treatment were associated with cancer complications. Conclusions NIBS appears to have an analgesic effect in cancer-related pain. However, due to the high heterogeneity of pain conditions, placebo-controlled trials with larger and homogeneous patient cohorts are required to confirm these promising results.
引用
收藏
页数:14
相关论文
共 57 条
[1]  
Glare P.A., Et al., Pain in cancer survivors, J Clin Oncol Off J Am Soc Clin Oncol, 32, 16, pp. 1739-1747, (2014)
[2]  
Snijders R.A.H., Brom L., Theunissen M., van den Beuken-van Everdingen M.H.J., Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis, Cancers, 15, 3, (2023)
[3]  
van den Beuken-van Everdingen M., Chronic pain in cancer survivors: a growing issue, J Pain Palliat Care Pharmacother, 26, 4, pp. 385-387, (2012)
[4]  
Moye J., June A., Martin L.A., Gosian J., Herman L.I., Naik A.D., Pain is prevalent and persisting in cancer survivors: differential factors across age groups, J Geriatr Oncol, 5, 2, pp. 190-196, (2014)
[5]  
Tevaarwerk A., Et al., Survivorship, version 1.2021: featured updates to the NCCN guidelines, J Natl Compr Canc Netw, 19, 6, pp. 676-685, (2021)
[6]  
Bennett M.I., Et al., The IASP classification of chronic pain for ICD-11: chronic cancer-related pain, Pain, 160, 1, pp. 38-44, (2019)
[7]  
Roberto A., Et al., Prevalence of neuropathic pain in cancer patients: pooled estimates from a systematic review of published literature and results from a survey conducted in 50 Italian palliative care centers, J Pain Symptom Manage, 51, 6, pp. 1091-1102.e4, (2016)
[8]  
Raja S.N., Et al., The revised international association for the study of pain definition of pain: concepts, challenges, and compromises, Pain, 161, 9, pp. 1976-1982, (2020)
[9]  
Kerckhove N., Collin A., Conde S., Chaleteix C., Pezet D., Balayssac D., Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review, Front Pharmacol, 8, (2017)
[10]  
Seretny M., Et al., Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis, Pain, 155, 12, (2014)